S&P 500   3,963.38 (-0.36%)
DOW   32,386.48 (-0.14%)
QQQ   306.05 (-0.88%)
AAPL   156.46 (-1.15%)
MSFT   273.08 (-1.19%)
META   199.31 (-1.74%)
GOOGL   100.63 (-1.79%)
AMZN   97.33 (-0.72%)
TSLA   186.36 (-2.84%)
NVDA   261.85 (-1.30%)
NIO   9.17 (+2.69%)
BABA   98.20 (+14.03%)
AMD   93.52 (-3.20%)
T   18.78 (-0.48%)
F   11.56 (+0.35%)
MU   58.53 (-2.11%)
CGC   1.85 (-1.60%)
GE   92.98 (-0.35%)
DIS   94.98 (-0.67%)
AMC   4.77 (+4.84%)
PFE   40.05 (-0.42%)
PYPL   72.19 (-1.51%)
NFLX   323.93 (-1.14%)
S&P 500   3,963.38 (-0.36%)
DOW   32,386.48 (-0.14%)
QQQ   306.05 (-0.88%)
AAPL   156.46 (-1.15%)
MSFT   273.08 (-1.19%)
META   199.31 (-1.74%)
GOOGL   100.63 (-1.79%)
AMZN   97.33 (-0.72%)
TSLA   186.36 (-2.84%)
NVDA   261.85 (-1.30%)
NIO   9.17 (+2.69%)
BABA   98.20 (+14.03%)
AMD   93.52 (-3.20%)
T   18.78 (-0.48%)
F   11.56 (+0.35%)
MU   58.53 (-2.11%)
CGC   1.85 (-1.60%)
GE   92.98 (-0.35%)
DIS   94.98 (-0.67%)
AMC   4.77 (+4.84%)
PFE   40.05 (-0.42%)
PYPL   72.19 (-1.51%)
NFLX   323.93 (-1.14%)
S&P 500   3,963.38 (-0.36%)
DOW   32,386.48 (-0.14%)
QQQ   306.05 (-0.88%)
AAPL   156.46 (-1.15%)
MSFT   273.08 (-1.19%)
META   199.31 (-1.74%)
GOOGL   100.63 (-1.79%)
AMZN   97.33 (-0.72%)
TSLA   186.36 (-2.84%)
NVDA   261.85 (-1.30%)
NIO   9.17 (+2.69%)
BABA   98.20 (+14.03%)
AMD   93.52 (-3.20%)
T   18.78 (-0.48%)
F   11.56 (+0.35%)
MU   58.53 (-2.11%)
CGC   1.85 (-1.60%)
GE   92.98 (-0.35%)
DIS   94.98 (-0.67%)
AMC   4.77 (+4.84%)
PFE   40.05 (-0.42%)
PYPL   72.19 (-1.51%)
NFLX   323.93 (-1.14%)
S&P 500   3,963.38 (-0.36%)
DOW   32,386.48 (-0.14%)
QQQ   306.05 (-0.88%)
AAPL   156.46 (-1.15%)
MSFT   273.08 (-1.19%)
META   199.31 (-1.74%)
GOOGL   100.63 (-1.79%)
AMZN   97.33 (-0.72%)
TSLA   186.36 (-2.84%)
NVDA   261.85 (-1.30%)
NIO   9.17 (+2.69%)
BABA   98.20 (+14.03%)
AMD   93.52 (-3.20%)
T   18.78 (-0.48%)
F   11.56 (+0.35%)
MU   58.53 (-2.11%)
CGC   1.85 (-1.60%)
GE   92.98 (-0.35%)
DIS   94.98 (-0.67%)
AMC   4.77 (+4.84%)
PFE   40.05 (-0.42%)
PYPL   72.19 (-1.51%)
NFLX   323.93 (-1.14%)
ASX:RAC

Race Oncology - RAC Stock Forecast, Price & News

Add
Compare
Today's Range
N/A
50-Day Range
N/A
52-Week Range
N/A
Volume
76,322 shs
Average Volume
N/A
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

RAC stock logo

About Race Oncology (ASX:RAC) Stock

Race Oncology Limited operates as a precision oncology company in Australia. The company is developing Zantrene, a potent small molecule inhibitor of the fatso/fat mass and obesity associated protein to treat for melanoma and clear cell renal cell carcinoma, as well as acute myeloid leukaemia, breast, and ovarian cancers, which is in Phase II/III clinical trial. It has a preclinical research program with the University of Newcastle for investigating Zantrene; and strategic collaboration with the University of Wollongong to evaluate Zantrene formulations. The company was formerly known as Coronado Resources Limited and changed its name to Race Oncology Limited in July 2016. Race Oncology Limited was incorporated in 2011 and is based in Sydney, Australia.

Receive RAC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Race Oncology and its competitors with MarketBeat's FREE daily newsletter.

RAC Stock News Headlines

"Prepare for Five Years of Famine"
Market Wizard who predicted all indexes would be negative in 2022 shares shocking new forecast
"Prepare for Five Years of Famine"
Market Wizard who predicted all indexes would be negative in 2022 shares shocking new forecast
Race Oncology is moving in the right direction: Pitt Street Research
Race Oncology receives human ethics approval for Zantrene trial
Race Oncology makes strong preclinical and clinical progress in 2022
Race Oncology welcomes positive pre-IND meeting for Zantrene
See More Headlines
Receive RAC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Race Oncology and its competitors with MarketBeat's FREE daily newsletter.

RAC Company Calendar

Last Earnings
2/27/2019
Today
3/28/2023

Industry, Sector and Symbol

Industry
Biotechnology
Sub-Industry
N/A
Sector
Medical
CIK
N/A
Fax
N/A
Employees
N/A
Year Founded
N/A

Profitability

Net Income
$-10,790,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$1.38 million
Book Value
A$0.19 per share

Miscellaneous

Free Float
N/A
Optionable
Not Optionable
Beta
1.61

Key Executives

  • Mr. Phillip R. Lynch
    CEO, MD & Director
  • Dr. Daniel Tillett
    Chief Scientific Officer & Exec. Director
  • Ms. Christina Manfre
    Chief Financial Officer
  • Dr. Ajay Duggal Dip Pharm Med
    MB ChB, MRCP, Interim Chief Medical Officer
  • Mr. Peter Gordon Webse B.Bus (Age 59)
    FCIS, FCPA, FGIA, M.A.I.C.D., MAICD, Company Sec.













RAC Stock - Frequently Asked Questions

How were Race Oncology's earnings last quarter?

Race Oncology Limited (ASX:RAC) announced its quarterly earnings results on Wednesday, February, 27th. The company reported ($0.03) EPS for the quarter.

What other stocks do shareholders of Race Oncology own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Race Oncology investors own include Mesoblast (MESO), Pilbara Minerals (PLS) and Mount Gibson Iron (MGX).

What is Race Oncology's stock symbol?

Race Oncology trades on the ASX under the ticker symbol "RAC."

How much money does Race Oncology make?

Race Oncology (ASX:RAC) has a market capitalization of $0.00 and generates $1.38 million in revenue each year. The company earns $-10,790,000.00 in net income (profit) each year or A($0.07) on an earnings per share basis.

How can I contact Race Oncology?

The official website for the company is www.raceoncology.com. The company can be reached via phone at 61 3 9097 1656.

This page (ASX:RAC) was last updated on 3/28/2023 by MarketBeat.com Staff